In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...
The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results